Yun Fan

Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial

Tony Mok, Yi‐Long Wu, Iveta Kudaba et al. · The Lancet · 2019 · 3.3K citations · Full text

Medicine, Oncology, Pharmacology +15

Osimertinib with or without Chemotherapy in <i>EGFR</i> -Mutated Advanced NSCLC

David Planchard, Pasi A. Jänne, Ying Cheng et al. · New England Journal of Medicine · 2023 · 650 citations · Full text

Medicine, Oncology, Pharmacology +7

Camrelizumab plus carboplatin and pemetrexed versus chemotherapy alone in chemotherapy-naive patients with advanced non-squamous non-small-cell lung cancer (CameL): a randomised, open-label, multicentre, phase 3 trial

Caicun Zhou, Gongyan Chen, Yunchao Huang et al. · The Lancet Respiratory Medicine · 2020 · 505 citations

Medicine, Oncology, Pharmacology +13

Sintilimab Plus Platinum and Gemcitabine as First-Line Treatment for Advanced or Metastatic Squamous NSCLC: Results From a Randomized, Double-Blind, Phase 3 Trial (ORIENT-12)

Caicun Zhou, Caicun Zhou, Lin Wu et al. · Journal of Thoracic Oncology · 2021 · 317 citations · Full text

Medicine, Oncology, Pharmacology +8

Ensartinib vs Crizotinib for Patients With Anaplastic Lymphoma Kinase−Positive Non–Small Cell Lung Cancer

Leora Horn, Ziping Wang, Gang Wu et al. · JAMA Oncology · 2021 · 245 citations · Full text

Medicine, Oncology, Pharmacology +14